Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Bristol-Myers Squibb Settles FCPA Case for $14 Million

Jaclyn Jaeger | October 5, 2015

Pharmaceutical giant Bristol-Myers Squibb today reached a $14 million settlement with the Securities and Exchange Commission for violations of the Foreign Corrupt Practices Act.

According to the SEC's order instituting the administrative proceeding, Bristol-Myers Squibb's joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales, reaping more than $11 million in profits from its misconduct. According to the SEC’s order instituting settled administrative proceedings, Bristol-Myers Squibb lacked effective internal controls over interactions with health care providers at BMS China, its majority-owned joint venture. 

Between 2009 and 2014, BMS China sales representatives sought to secure and increase business by providing...

Read this single article for $49, or click the subscribe button below to review subscription options.

Enjoy unlimited access to thousands of articles, browse five years of digital magazines, qualify for reduced admission to events, and more.